Save the date for the Annual Gastrointestinal Oncology Symposium, hosted by Karmanos Cancer Institute. The symposium is geared towards general physicians, surgeons, fellows, residents, students, pathologists, radiation oncologists, pharmacists, physician assistants, nurse practitioners, and nurses in the field of hematology and oncology. Please contact Pamela Sydorchuk, symposium coordinator, at [email protected] or call 313-576-8746 with any questions.
AACI Update | September 2026
Headlines
Roberts Named President and CEO of St. Jude Children's Research Hospital
Following an extensive international search, the Board of Governors of St. Jude Children’s Research Hospital announced Charles W.M. Roberts, MD, PhD, executive vice president and current director of the St. Jude Comprehensive Cancer Center, as its next president and chief executive officer, effective January 1, 2027. As the hospital's seventh president and CEO, Roberts will oversee a global organization dedicated to advancing cures and means of prevention for pediatric catastrophic diseases.
Pisters to Retire, Interim President Named for The University of Texas MD Anderson Cancer Center
Peter W.T. Pisters, MD, announced his plans to retire from UT MD Anderson Cancer Center after nine years as president. The UT System Board of Regents and Chancellor John M. Zerwas, MD, have named Jeffrey E. Lee, MD, interim president, effective immediately. Dr. Pisters will work with Dr. Lee on a thoughtful transition through the end of September.
Three New Members Elected to AACI Board
AACI has elected Jonathan W. Friedberg, MD, MMSc; Primo N. Lara, Jr., MD; and Matthew Vander Heiden, MD, PhD, to its Board of Directors. The new board members will begin three-year terms during the 2026 AACI/CCAF Annual Meeting, when they will replace outgoing board members Raymond N. DuBois, MD, PhD, and Yolanda (Yoli) Sanchez, PhD.
Mass General Brigham Cancer Institute is Newest AACI Member
AACI is pleased to welcome Mass General Brigham Cancer Institute as its newest cancer center member. Led by President David Ryan, MD, the cancer institute delivers comprehensive cancer care to patients in its New England catchment area, spanning eastern Massachusetts, the North Shore, and southern New Hampshire, with a focus on populations served by Mass General Brigham community health centers.
AACI Announces New CRI Steering Committee Members
Pictured, clockwise from top left: Dr. Edward J. Kim, Stephanie Brogan, Dr. Wencesley A. Paez, and Kelli Thorne
The AACI Clinical Research Innovation (CRI) Steering Committee is pleased to announce the appointment of Edward J. Kim, MD, PhD, as its new chair-elect. We are also excited to welcome three new steering committee members: Stephanie Brogan, CCRP; Wencesley A. Paez, MD, MS; and Kelli Thorne, MPH, CCRP.
AACI Announces PCLI Leadership Transition
Pictured, left to right: Drs. Lee G. Wilke and Paula M. Fracasso
Lee G. Wilke, MD, FACS, senior medical director of clinical cancer services at UW Health and the University of Wisconsin Carbone Cancer Center, is the new chair of AACI's Physician Clinical Leadership Initiative (PCLI) Steering Committee, replacing Paula M. Fracasso, MD, PhD, who has stepped down as PCLI chair following a change in her role at VCU Massey Comprehensive Cancer Center.
NCI Director to Present at Annual Meeting
National Cancer Institute (NCI) Director Anthony Letai, MD, PhD, will report on the current status of the national cancer research enterprise at 11:15 am central time on Tuesday, October 27, during the closing session of the 2026 AACI/CCAF Annual Meeting. A longstanding highlight of the annual meeting, the NCI Director's Report provides crucial updates on funding mechanisms, priorities, and goals for NCI-Designated Cancer Centers.
Register for Our Next PCLI Webinar: Innovating Cancer Genetics Programs
Pictured, clockwise from top left: Dr. Jason Fleming, Dr. Christine Hong, Sara Pirzadeh-Miller, and Dr. Rachel Wooldridge
AACI's Physician Clinical Leadership Initiative (PCLI) will host a webinar titled “Innovating Cancer Genetics Programs: From Pharmacogenomics to Longitudinal Prevention" at 1:00 pm eastern time on Tuesday, September 15. Attendees will gain insight into the development of standardized clinical workflows, lessons learned from implementing these initiatives, and early program outcomes.
Paradigm Health and AACI to Present Webinar on 'Pioneering a Modern Regulatory Framework'
Pictured, clockwise from top left: Dr. Ivy Altomare and Kent Thoelke of Paradigm Health; Jeremy Walsh, formerly of U.S. FDA; and Dr. Emma Meagher of Perelman School of Medicine, University of Pennsylvania
Paradigm Health and AACI will present a webinar titled “Pioneering a Modern Regulatory Framework: a Discussion With the Leaders Behind FDA’s Real-Time Clinical Trials” at 11:00 am eastern time on Monday, September 28. Learn more about the landmark initiative from some of the pioneers at the center of the FDA’s proof-of-concept trials.
Nominate an Emerging Leader for 2026 LDW and New Yearlong Training Program
Nominations for the new AACI Leadership Advancement Program (LAP) and the Leadership Development Workshop (LDW) are due by 8:00 pm eastern time on Wednesday, September 30. Directors of AACI member cancer centers are encouraged to select an emerging leader for each program. The LDW provides an opportunity for emerging cancer center leaders to strengthen their leadership skills. The yearlong LAP is designed for those who are registered for the 2026 LDW or have already participated in a past workshop.
AACI Comments on Proposed Changes to 340B Program
Last month, AACI submitted comments in response to Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-2026-2344), proposed by the Centers for Medicare & Medicaid Services (CMS). Throughout its comments, AACI noted that the proposed rule does not keep pace with sustained increases in operating costs for cancer centers and shared concerns with provisions related to site-neutral payments, 340B reimbursement, and new provider requirements.
Paid Advertisement: Mayo Clinic Comprehensive Cancer Center
Mayo Clinic Comprehensive Cancer Center is currently seeking a highly skilled and experienced Executive Administrator. You’ll partner with our Executive Cancer Center Director to lead a world-class, multidisciplinary team in a high-performance research ecosystem in our laboratories, clinics, and communities. Discover a life-changing career today!
News from the Centers
Ley Elected to American Philosophical Society
Siteman Cancer Center
Timothy J. Ley, MD, a professor of medicine and of genetics at WashU Medicine, the Lewis T. and Rosalind B. Apple Chair in Oncology at Barnes-Jewish Hospital, and a research member at Siteman Cancer Center, has been elected as a member of the American Philosophical Society. The society was founded by Benjamin Franklin in 1743 to “promote useful knowledge.”
Lonial to Receive Lifetime Achievement Award From International Myeloma Society
Winship Cancer Institute of Emory University
Sagar Lonial, MD, FACP, FASCO, chief medical officer of Winship Cancer Institute and chair of Emory's Department of Hematology and Medical Oncology, has been named the 2026 recipient of the Waldenström Lifetime Achievement Award from the International Myeloma Society. He will receive the honor during the 23rd Annual Meeting of the International Myeloma Society.
Roswell Park Named Optum Center of Excellence for Adult and Pediatric Stem Cell Transplants
Roswell Park Comprehensive Cancer Center
Optum, a health services company, has again recognized Roswell Park Comprehensive Cancer Center as a Center of Excellence for its adult and pediatric stem cell transplant programs. Certification requires an evaluation process conducted by Optum’s Clinical Sciences Institute assessing factors like clinical expertise, patient outcomes, and quality of care to ensure the center meets specific criteria.Fox Chase Cancer Center Recognized Among Nation's Best for Cancer Care, Urology
Fox Chase Cancer Center, Temple Health
Fox Chase Cancer Center was recognized in the U.S. News & World Report 2026-27 Best Hospitals rankings. The cancer center ranked number 32 for cancer care and treatment and number 11 for urology.
Winship Awarded $10.9M Lung Cancer SPORE Grant
Winship Cancer Institute of Emory University
Winship Cancer Institute has been awarded a five-year, $10.9 million Specialized Program of Research Excellence (SPORE) grant from the National Cancer Institute. Led by Suresh S. Ramalingam, MD, and Haian Fu, PhD, the Winship Lung Cancer SPORE will address critical challenges in non-small cell lung cancer. Dr. Ramalingam is Winship's executive director and a member of AACI's Board of Directors.
Angeles Receives $4.6M NCI Grant to Study Role of Memory T Cells in Melanoma
University of Michigan Rogel Cancer Center
Christina V. Angeles, MD, associate professor of surgery and dermatology at Michigan Medicine, received a $4.6 million grant from the National Cancer Institute to understand the role tissue-resident memory T cells play in the spread of melanoma and its response to immunotherapy. The research is expected to inform clinical trials focused on inducing durable immunity to cancer and improving survival.
$2.6M NCI Grant to Fund Metastasis Research
UMMC Cancer Center and Research Institute
UMMC Cancer Center and Research Institute was awarded a $2.6 million National Cancer Institute (NCI) grant to study prostate cancer bone metastasis. The five-year study, led by Jawed Siddiqui, PhD, will center on the role of protein lipoylation and mitochondrial metabolism in guiding prostate cancer cells to the bones, and the importance of cuproptosis, a form of cell death.
NCI Awards $2M Grant to Study Role of Cholesterol in Pancreatic Cancer Survival
Stephenson Cancer Center, University of Oklahoma
Surendra Shukla, PhD, of Stephenson Cancer Center, has received a five-year, $2 million grant from the National Cancer Institute (NCI) to investigate how pancreatic cancer uses cholesterol to survive chemotherapy. By uncovering how tumors use this essential nutrient to grow and evade treatment, the research could identify new ways to treat one of the deadliest forms of cancer.
$1.75M Grant to Expand Lung Cancer Screening
Sidney Kimmel Comprehensive Cancer Center at Jefferson
Jefferson Health received a $1.75 million Bristol Myers Squibb Foundation grant to develop and test a replicable model for improving lung cancer screening access and early detection among medically underserved populations in Philadelphia. Led by Julie A. Barta, MD, the three-year project will partner with the Health Federation of Philadelphia and community health centers.
Bacik Tapped as CEO of New MUSC Comprehensive Cancer Hospital
Hollings Cancer Center, Medical University of South Carolina
Adam Bacik has been named CEO of the MUSC comprehensive cancer hospital, slated for completion in 2030. Bacik will direct efforts related to oncology services, cancer care expansion, and hospital development.
Kremyanskaya Named Chief Quality Officer
Mount Sinai Tisch Cancer Center
Marina Kremyanskaya, MD, PhD, has been named chief quality officer at the Mount Sinai Tisch Cancer Center. Dr. Kremyanskaya will lead initiatives to advance clinical quality and patient safety across cancer care delivery sites throughout the health system. She previously served as medical director of the Inpatient Hematologic Malignancies Services at The Mount Sinai Hospital.
Thompson to Lead Vera Bradley Foundation Center for Breast Cancer Research
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The IU Simon Comprehensive Cancer Center has recruited Alastair Thompson, MD, an internationally recognized breast cancer physician-scientist, to serve as director of its Vera Bradley Foundation Center for Breast Cancer Research.
Ozbun Named Associate Director for Basic Research at UNMCCC
University of New Mexico Comprehensive Cancer Center
Michelle Ozbun, PhD, has been named associate director for basic research at UNM Comprehensive Cancer Center. An internationally recognized leader in human papillomavirus research, Dr. Ozbun is a distinguished professor and the Maralyn S. Budke Endowed Professor in Viral Oncology in the UNM Department of Molecular Genetics & Microbiology and the Department of Obstetrics & Gynecology.
Kaffenberger Named Deputy Director of Cancer Clinical Services
University of Michigan Rogel Cancer Center
The University of Michigan Rogel Cancer Center has named Samuel Kaffenberger, MD, as deputy director for cancer clinical services, a role that complements his current position as senior medical director for cancer services at Michigan Medicine. Dr. Kaffenberger was also named medical director of clinical operations for the cancer center.
Bur Appointed to Positions at Siteman, WashU Medicine
Siteman Cancer Center
Andrés M. Bur, MD, FACS, has been named chief of Head and Neck Surgery at WashU Medicine and co-director of the Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center.
UF Health Cancer Institute Announces Research Program Leadership Changes
UF Health Cancer Institute
Ramon Sun, PhD, a biochemist and molecular biologist, has been named co-leader of the UF Health Cancer Institute’s Mechanisms of Oncogenesis research program. Weizhou Zhang, PhD, who is leading novel research on cancer immunotherapeutics, was named co-leader of the Immuno-Oncology and Microenvironment research program.
Combination Therapies Overcome Treatment Resistance in Advanced Prostate Cancer
UCLA Jonsson Comprehensive Cancer Center
UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against metastatic castration-resistant prostate cancer. In lab and animal models, combining antibody-drug conjugates with a drug that blocks a cancer cell survival protein called BCL-XL triggered greater cancer cell death and slowed tumor growth.
CS18: a New Drug That Can Potentially Overcome Cancer Drug Resistance
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts the ability of cancer cells to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.For Early Prostate Cancer, 'Active Surveillance' is Now No. 1 Choice
UCSF Helen Diller Family Comprehensive Cancer Center
A new study by UC San Francisco and the San Francisco VA Health Care System of more than 73,000 veterans enrolled in the VA system found most veterans now pursue active surveillance instead of treatment for low-risk and favorable intermediate risk prostate cancers. Studies have shown similar survival outcomes for surveillance compared to treatment, with lower risks of urinary incontinence, bowel problems, or erectile dysfunction.
Fox Chase Study Reveals How the Genome Responds to Epigenetic Change
Fox Chase Cancer Center, Temple Health
Researchers at Fox Chase Cancer Center found that epigenetic changes, chemical modifications that affect gene activity without altering the DNA sequence, can reshape the way DNA is organized inside cells, a process increasingly linked to cancer and other diseases. The study showed that these changes can alter three-dimensional genome structure in ways that may influence cancer treatment. The findings were published in Nature Communications.
Giving Appalachian Communities a Stronger Voice in Tobacco Regulations
UK Markey Cancer Center
A new research model developed by the University of Kentucky’s Appalachian Tobacco Regulatory Science Team (AppalTRUST), including UK Markey Cancer Center researchers, shows strong early success in engaging rural Appalachian adults in research on tobacco.
Johns Hopkins Liver Cancer Experts Co-Author New Hepatocellular Carcinoma Treatment Framework
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Liver cancer experts at the Johns Hopkins Kimmel Cancer Center and 16 other cancer centers have compiled new guidance on the best treatments for hepatocellular carcinoma (HCC) in North America. The resource, called BEACON-HCC, was published Aug. 7 in the journal Hepatology by HCC-LIVE, a consortium of North American experts in HCC.New Approach Improves Survival, Reduces Recurrence for Muscle-Invasive Bladder Cancer
Mount Sinai Tisch Cancer Center
Researchers led by Matthew Galsky, MD, at the Mount Sinai Tisch Cancer Center, have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery. Findings from the international Phase III clinical trial were published in The New England Journal of Medicine.
Practice-Changing Breast Cancer Discovery Stems From Decades of Research
Huntsman Cancer Institute at the University of Utah
Building on two decades of work led by Huntsman Cancer Institute's Philip Bernard, MD, results of the OPTIMA Phase III clinical trial indicate that some breast cancer patients can safely avoid chemotherapy. The multi-institutional collaboration produced the Prosigna (PAM50) genetic expression test.
Protein That Repairs Bone Marrow Identified in Study
Cedars-Sinai Cancer
Cedars-Sinai investigators have identified a protein that could help replenish the blood supply for patients treated with chemotherapy or radiation. The preclinical study, published in Blood, could yield future treatments that help cancer patients recover faster after chemotherapy and radiation.
Researchers Develop New Drug for Aggressive Leukemias
UF Health Cancer Institute
UF Health Cancer Institute researchers have created a drug that effectively kills aggressive leukemia cells in mouse models and human samples by targeting both NR4A1 and IKKβ. NR4A1 has been thought to suppress acute myeloid leukemia, but the researchers provide novel evidence that it can promote certain subtypes. More testing and characterization of patients who could benefit from the treatment will be needed to move it to clinical trials in humans.Social Determinants of Health Linked to More Fatalistic Cancer Beliefs
Sidney Kimmel Comprehensive Cancer Center at Jefferson
New research from Thomas Jefferson University shows that greater cumulative exposure to adverse social determinants of health is associated with beliefs that cancer is unavoidable or is a death sentence. This can influence whether people choose to be screened for common cancers or seek treatment after diagnosis. The study is also among the first to examine the total burden of social determinants on cancer beliefs.Study Shows Promise of New Approach to Lung Cancer Treatment
Stony Brook Cancer Center
New findings by a research team from Stony Brook Cancer Center highlight a novel therapeutic shown to be highly effective in reducing non-small cell lung cancer tumors and appears to halt drug resistance in a laboratory model. Led by Jingfang Ju, PhD, the team combined the natural cancer-fighting molecule miR-129 with the chemotherapy drug gemcitabine to create Gem-miR-129. This drug enters cancer cells on its own without the need of a delivery vehicle and simultaneously shut down three different oncogenic driver proteins that help lung cancer grow and resist therapy. The paper is published early online in the journal Molecular Therapy.
Discovery of Hidden Survival Strategy of Antibiotic-Tolerant Bacteria Could Be Relevant for Pediatric Cancer Patients
Comprehensive Cancer Center St. Jude Children's Research Hospital
Researchers have uncovered a previously hidden survival strategy that allows bacteria to temporarily withstand antibiotics, not by becoming genetically resistant, but by entering a reversible "tolerant" state driven by changes in RNA regulation. The findings are especially relevant for children with weakened immune systems, including pediatric cancer patients, who are at greater risk of life-threatening bacterial infections caused by pathogens.
Can Mini Organs Help Predict Breast Tumor Response to Therapy?
UCSF Helen Diller Family Comprehensive Cancer Center
Researchers at UCSF have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from an innovative clinical trial called I-SPY and rapid experimentation on lab-grown mini tumors.
Experimental Synthetic mRNA Platform May Lead to Faster, More Effective Therapeutics for Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including vaccines fighting against infectious disease, cancer, and autoimmune conditions, faster and more efficiently than the industry standard.New Method Could Boost Monitoring Value of Colon Cancer Blood Test
Cedars-Sinai Cancer
Cedars-Sinai Health Sciences University study results published in Experimental Hematology & Oncology suggest blood tests could become a more powerful tool for monitoring colon cancer progression and treatment response. Investigators analyzed blood samples from patients with advanced colorectal cancer, looking at 10 different cellular characteristics and using single-cell analysis to refine their findings. The method reveals important changes that would be missed with existing tests. If validated in larger studies, the method could complement existing tools for cancer monitoring.
Researchers Uncovered How Loss of NF1 Drives ER+ Breast Cancer to Metastasize to the Bone
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
A Baylor College of Medicine-led team has uncovered how loss of tumor suppressor neurofibromin (NF1) in estrogen receptor-positive (ER+) breast cancer cells drives the cells’ preference to metastasize to the bone. The findings, published in Cancer Letters, suggest that NF1 loss functionally links therapy resistance with increased bone metastatic potential and support investigating whether matching patient NF1 tumor status with current approved therapies can effectively reduce the incidence of bone metastasis.Women Diagnosed Within Three Years of Childbirth May Face More Aggressive Breast Cancer
UCLA Jonsson Comprehensive Cancer Center
Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth, according to a new study led by investigators at UCLA Jonsson Comprehensive Cancer Center. The findings, published in the journal npj Breast Cancer, add to growing evidence that postpartum breast cancer may represent a distinct form of the disease and suggest the period of greatest biological risk may occur earlier than previously thought.
Combination Treatment Shows Promise in Pediatric Leukemia Patients
Roswell Park Comprehensive Cancer Center
A combination treatment in development at Roswell Park could give more kids with pediatric leukemia a chance to grow up. Lisa Niswander, MD, PhD, a physician-scientist and pediatric oncologist, is investigating ways to combine two new but proven therapies, CAR T cells and a new class of targeted cancer drugs, to see if they can work better together to combat leukemia in the youngest patients.
Huntsman Surgical Team Performs First Robotic Mastectomy in Mountain West
Huntsman Cancer Institute at the University of Utah
A surgical team from Huntsman Cancer Institute at the University of Utah performed the first robotic nipple-sparing mastectomy in the Mountain West, making it one of only a small number of cancer centers in the United States offering the procedure. The robotic technique offers eligible patients a less invasive surgical option with smaller, less visible scars.AACI Joins Cancer Center Community in Mourning Loss of Patient Navigation Pioneer
Association of American Cancer Institutes
Photo by Randy Belice
Surgical oncologist Harold P. Freeman, MD, died August 11, 2026, at age 93. Dr. Freeman was a pioneer of health equity research and a familiar face to the AACI community, most recently joining a panel discussion on the future of patient navigation during the 2024 AACI/CCAF Annual Meeting in Chicago.
Record Fundraising at UAMS Includes Cancer Center Donations
UAMS Winthrop P. Rockefeller Cancer Institute
A record-breaking fundraising year for the University of Arkansas for Medical Sciences extended to the Rockefeller Cancer Institute. Donations to the institution included a $5 million gift from Anne and Merritt Dyke to support clinical services at the Anne Dyke Breast Center, $2.8 million raised during the Winthrop P. Rockefeller Cancer Institute’s Gala for Life, and two $500,000 gifts in honor of Jonnie Kay Westbrook.Cancer Center Jobs
Director, Division of Hematology/Oncology
O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham
Read moreAssociate Director of Clinical Research Operations (IIT & Program Strategy Focus)
Washington University School of Medicine
Read moreMeeting Announcements
Annual Gastrointestinal Oncology Symposium
September 19, 2026
Cancer Center Community Impact Forum
September 27, 2026
The Cancer Center Community Impact Forum (CCCIF) is a national annual meeting of NCI Designated Cancer Center professionals and professionals at cancer centers working towards designation who are dedicated to advancing community-engaged cancer control. The meeting is hosted by the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium.
2026 AACI Leadership Development Workshop
October 24, 2026
The 2026 AACI Leadership Development Workshop will be held in conjunction with the 2026 AACI/CCAF Annual Meeting.
This event convenes emerging leaders for didactic and experiential leadership development sessions. An offshoot of Dr. Caryn Lerman’s AACI presidential initiative, the workshop aims to enhance the oncology leadership pipeline with top talent.
Support Opportunities
2026 Impact Summit
October 24, 2026
The 2026 Impact Summit will be held in conjunction with the 2026 AACI/CCAF Annual Meeting.
Co-hosted by AACI and the Cancer Center Network, the Impact Summit brings together cancer center leaders, researchers, and other stakeholders for a dynamic one-day event focused on strengthening the future of cancer center leadership and workforce development.
Support Opportunities
2026 New Cancer Center Directors Meeting
October 24, 2026
The 2026 New Cancer Center Directors Meeting will be held in conjunction with the 2026 AACI/CCAF Annual Meeting. Participation in this meeting is by invitation only. Please contact AACI Program Coordinator Chloe Boothby with any questions.
2026 AACI/CCAF Annual Meeting
October 25, 2026
The 3-day AACI/CCAF annual meeting offers AACI members the opportunity to network with cancer center colleagues, national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges.
Support Opportunities
Save the Date: 2026 AACI Government Relations Forum
October 26, 2026
2:00 PM - 5:00 PM
Save the date for the 2026 AACI Government Relations (GR) Forum. The GR Forum will be held from 2:00 to 5:00 pm central time on Monday, October 26, in conjunction with the 2026 AACI/CCAF Annual Meeting at the Chicago Marriott Downtown Magnificent Mile. More details will be shared as they become available.
Save the Date: Gordon Ginder Innovations in Cancer Symposium: ELEVATE Liver Cancer & MASH
April 8, 2027
Save the date for the VCU Massey Comprehensive Cancer Center's 2-day Gordon Ginder Innovations in Cancer Symposium: Liver Cancer and MASH, presented by Massey's ELEVATE P01 Program and the VCU Stravitz-Sanyal Institute. Registration coming soon.
Save the Date: 2027 AACI/AACR Hill Day
May 20, 2027
Save the date for the 2027 AACI/AACR Hill Day. More information to come.
Save the Date: 19th Annual AACI CRI Meeting
June 28, 2027
Save the date for the 19th Annual AACI Clinical Research Innovation (CRI) Meeting, June 28-30, 2027, at the Loews Chicago O'Hare Hotel in Rosemont, IL.